Life Science Investing Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
Life Science Investing Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium
Life Science Investing Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access
Life Science Investing Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring
Life Science Investing New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response
Life Science Investing Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients
Life Science Investing Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering
Life Science Investing Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033
Life Science Investing Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Life Science Investing FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo for Treatment of ESR1-mutated Advanced Breast Cancer
